Double whammy: RNAi enhances lung cancer therapy
21 Mar 2012
Non-small cell lung cancer (NSCLC), the most common form of lung cancer, is usually treated with surgery and chemotherapy. However, a small group of patients can also be helped by treatment with tyrosine kinase inhibitors (TKI). New research published in BioMed Central’s open access journal BMC Medicine, shows that blocking production of epidermal growth factor receptor (EGFR) using RNAi, alongside TKI (or antibody therapy), could enhance the effect of TKI on NSCLC cell death, and slow cell growth.
There are 1.2 million new cases of lung cancer worldwide every year and about 75-85% of these are NSCLC. 10% of cases with NSCLC have a mutation in the gene responsible for making EGFR, and three quarters of these patients respond well to TKIs. However others are unresponsive, and, even for the people who responded at first, the cancer always ultimately becomes resistant to TKI therapy.
In an attempt to circumvent this problem researchers from Universitair Ziekenhuis Brussel, in Belgium, tested the effect of adding RNAi to standard TKI or antibody therapy in NSCLC cells. Proteins are made in the cell’s cytoplasm, but DNA is stuck inside the nucleus. Consequently, in order to produce a protein, a cell must first copy the gene’s DNA sequence, producing an intermediary molecule called RNA which is able to travel out of the nucleus to the cytoplasm. RNAi ‘interferes’ with the mechanism for producing proteins by blocking proper function of the intermediary RNA stage.
A team led by Prof De Grève and his co-worker, Gang Chen, found that the small interfering RNA (siRNA) molecule they designed was able to inhibit EGF protein production in all the NSCLC cell lines tested. It was also able to slow down cell growth and increase cell death (apoptosis) in all the cell lines – although some responded better than others. When they tested siRNA alongside TKI and or monoclonal antibodies they discovered that the siRNA had an additional positive effect on the cell lines than the standard treatment alone.
Prof De Grève explained, “Some EGFR mutations were more sensitive to siRNA than others - we saw especially good results against the mutation in exon 19. We think that this reflects the fact that the growth of cells with this mutation is driven by EGFR, but that other mutations are not as active. A different EGFR mutation produces cells which cannot be inhibited by TKI, however even these cells were sensitive to siRNA.”
These results provide hope for NSCLC patients with EGFR mutations, as it could potentially enhance TKI therapy. It may also help those who do not respond to TKI, or who have become resistant to TKI therapy. Additionally this treatment may benefit another group of patients where the gene for EGFR is too active in their cancer and too much EGFR is produced.
Dr Hilary Glover
Scientific Press Officer, BioMed Central
Tel: +44 (0) 20 3192 2370
Mob: +44 (0) 778 698 1967
Notes to Editors
1. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with Tyrosine Kinase inhibitors or Cetuximab
Gang Chen, Peter Kronenberger, Erik Teugels, Ijeoma Adaku Umelo and Jacques De Grève
BMC Medicine 2012, 10:28 doi:10.1186/1741-7015-10-28
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central’s open access policy.
Article citation and URL available on request on the day of publication.
2. BMC Medicine - the flagship medical journal of the BMC series - publishes original research articles, commentaries and reviews in all areas of medical science and clinical practice. To be appropriate for BMC Medicine, articles need to be of outstanding quality, broad interest and special importance. BMC Medicine (ISSN 1741-7015) is indexed/tracked/covered by PubMed, MEDLINE, BIOSIS, CAS, EMBASE, Scopus, Current Contents, Thomson Reuters (ISI) and Google Scholar.